Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock Position Increased by Atlantic Union Bankshares Corp

Atlantic Union Bankshares Corp lifted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 24.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,125 shares of the pharmaceutical company’s stock after purchasing an additional 999 shares during the period. Atlantic Union Bankshares Corp’s holdings in Vertex Pharmaceuticals were worth $2,085,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Arthur M. Cohen & Associates LLC grew its holdings in Vertex Pharmaceuticals by 3.2% during the fourth quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after purchasing an additional 25 shares during the period. Cooper Financial Group grew its holdings in Vertex Pharmaceuticals by 1.0% during the third quarter. Cooper Financial Group now owns 3,020 shares of the pharmaceutical company’s stock worth $1,050,000 after purchasing an additional 29 shares during the period. Arjuna Capital grew its holdings in Vertex Pharmaceuticals by 0.7% during the third quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock worth $1,521,000 after purchasing an additional 29 shares during the period. West Family Investments Inc. grew its holdings in Vertex Pharmaceuticals by 1.2% during the second quarter. West Family Investments Inc. now owns 2,494 shares of the pharmaceutical company’s stock worth $878,000 after purchasing an additional 30 shares during the period. Finally, FRG Family Wealth Advisors LLC boosted its holdings in shares of Vertex Pharmaceuticals by 0.9% during the third quarter. FRG Family Wealth Advisors LLC now owns 3,292 shares of the pharmaceutical company’s stock worth $1,145,000 after acquiring an additional 30 shares during the period. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Up 0.2 %

NASDAQ:VRTX traded up $0.69 on Friday, hitting $418.01. The stock had a trading volume of 1,092,126 shares, compared to its average volume of 1,045,136. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99. The stock has a market cap of $107.98 billion, a P/E ratio of 30.09, a price-to-earnings-growth ratio of 2.27 and a beta of 0.35. Vertex Pharmaceuticals Incorporated has a 1 year low of $310.90 and a 1 year high of $448.40. The firm’s fifty day simple moving average is $422.47 and its two-hundred day simple moving average is $391.24.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating analysts’ consensus estimates of $3.85 by $0.35. The firm had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. During the same period in the prior year, the firm earned $3.33 EPS. Analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on VRTX. JPMorgan Chase & Co. boosted their price objective on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a report on Thursday, February 1st. Robert W. Baird cut shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price objective on the stock. in a research note on Wednesday, January 31st. Truist Financial boosted their price objective on shares of Vertex Pharmaceuticals from $456.00 to $508.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Maxim Group cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $440.00 price target on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 20th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $417.27.

Insider Transactions at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Chairman Jeffrey M. Leiden sold 6,648 shares of the business’s stock in a transaction on Monday, January 8th. The shares were sold at an average price of $419.07, for a total value of $2,785,977.36. Following the completion of the sale, the chairman now directly owns 2,423 shares of the company’s stock, valued at $1,015,406.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Chairman Jeffrey M. Leiden sold 6,648 shares of the stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $419.07, for a total transaction of $2,785,977.36. Following the sale, the chairman now owns 2,423 shares in the company, valued at $1,015,406.61. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the transaction, the chief operating officer now owns 75,718 shares in the company, valued at $31,819,732.32. The disclosure for this sale can be found here. In the last ninety days, insiders sold 19,029 shares of company stock valued at $7,989,227. Insiders own 0.40% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.